The April 2026 final order from Acting Attorney General Todd Blanche immediately moved FDA-approved marijuana products and state-licensed medical marijuana to Schedule III under the Controlled Substances Act via treaty authority, providing tax relief under Section 280E for qualifying operators while leaving adult-use and other forms in Schedule I. A separate expedited DEA administrative hearing on broader rescheduling to Schedule III ran from June 29 to July 15, 2026, with mostly opposing participants selected and post-hearing briefs filed in August. Ongoing D.C. Circuit litigation challenges the April order, and no final rule on full rescheduling has emerged despite the December 2025 executive order directing an expeditious process. These procedural steps, participant selection, and legal hurdles shape trader consensus on timelines for any further change.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated$802,588 Vol.
September 30
2%
December 31
26%
$802,588 Vol.
September 30
2%
December 31
26%
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Market Opened: Feb 7, 2026, 5:04 PM ET
Resolver
0x65070BE91...The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Resolver
0x65070BE91...The April 2026 final order from Acting Attorney General Todd Blanche immediately moved FDA-approved marijuana products and state-licensed medical marijuana to Schedule III under the Controlled Substances Act via treaty authority, providing tax relief under Section 280E for qualifying operators while leaving adult-use and other forms in Schedule I. A separate expedited DEA administrative hearing on broader rescheduling to Schedule III ran from June 29 to July 15, 2026, with mostly opposing participants selected and post-hearing briefs filed in August. Ongoing D.C. Circuit litigation challenges the April order, and no final rule on full rescheduling has emerged despite the December 2025 executive order directing an expeditious process. These procedural steps, participant selection, and legal hurdles shape trader consensus on timelines for any further change.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated



Beware of external links.
Beware of external links.
Frequently Asked Questions